Who is BlueRock?
BlueRock Therapeutics LP is a clinical stage cell therapy harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, bemdaneprocel (BRT-DA01) for the treatment of Parkinson’s disease and OpCT-001 for the treatment of primary photoreceptor diseases are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves.
What Are We Doing?
Our foundational science harnesses the ability to create and then direct the differentiation of universal pluripotent stem cells into authentic, functional cells that can be used as allogeneic cellular therapies to treat a broad array of diseases. We can also further engineer these cells, enabling them to produce enzymes, antibodies, and other proteins for additional therapeutic benefit.
We are passionate about delivering on the promise of cellular and gene therapy, shaping the future of cellular medicine, and delivering new therapies to millions of patients with treatment options.
We are seeking individuals who are collaborative, thrive in a fun and dynamic culture, and are steadfast in the commitment to advance cutting-edge cellular therapies to impact patients’ lives.
The Myeloid Platform team is developing next‑generation microglia‑based therapeutics for neurodegenerative and neuroinflammatory diseases. The Myeloid Platform Co-Op is responsible for the development of complex in vitro model of neurodegenerative diseases to further BlueRock’s drug development pipeline. This role places the co‑op at the center of cutting‑edge research involving human iPSC‑derived microglia, neural co‑culture systems, and translational assay development. The successful candidate will act as part of the Myeloid platform team and will collaborate with other groups such as Discovery Analytics and Bioinformatics to generate sound scientific evidence to support and drive the company’s preclinical pipeline.